Insulin aspart, recombinant Subcutaneous and Obinutuzumab Intravenous
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Obinutuzumab Intravenous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: obinutuzumab
Brand name: Gazyva
Synonyms: Obinutuzumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Obizur
- Insulin aspart, recombinant Subcutaneous-Obizur Intravenous
- Insulin aspart, recombinant Subcutaneous-Obredon
- Insulin aspart, recombinant Subcutaneous-Ocaliva
- Insulin aspart, recombinant Subcutaneous-Occlucort
- Insulin aspart, recombinant Subcutaneous-Occlusal-HP Topical
- Obinutuzumab Intravenous-Insulin degludec
- Obinutuzumab Intravenous-Insulin Degludec (U-100) Prefilled Pens
- Obinutuzumab Intravenous-Insulin Degludec (U-100) Vials
- Obinutuzumab Intravenous-Insulin Degludec (U-200) Prefilled Pens
- Obinutuzumab Intravenous-Insulin degludec and liraglutide
- Obinutuzumab Intravenous-Insulin degludec and liraglutide Subcutaneous